<b>Conclusions:</b> This study reveals ZYBSW can effectively alleviate CGN, with EGFR and DUSP1 as likely therapeutic targets, and its mechanism of action primarily involves regulating the MAPK signaling pathway. The gene discussed is EGFR; the disease is childhood gender nonconformity.